» » »

Chemo Regimen for Ovarian Cancer Durham NC

Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients in Durham, according to the new study findings.

Cary N Robertson MD
(919) 681-6788
DUMC 3833
Durham, NC
Specialties
Urology

Data Provided by:
Johannes Vieweg, MD
(919) 684-9949
MSRB Room 455 Box 2626,
Durham, NC
Specialties
Urology
Gender
Male
Education
Medical School: Tech Univ, Fak Med, Munchen, Germany
Graduation Year: 1988

Data Provided by:
Bassem M Eldaif, MD
(919) 684-5693
Box 2922,
Durham, NC
Specialties
Urology
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
John Saml Wiener, MD
(919) 684-6994
P O Box 3831,
Durham, NC
Specialties
Urology
Gender
Male
Education
Medical School: Tulane Univ Sch Of Med, New Orleans La 70112
Graduation Year: 1988
Hospital
Hospital: Univ Of Mississippi Med Ctr, Jackson, Ms
Group Practice: University Surgical Associates Llp

Data Provided by:
Judd Wendell Moul, MD
(919) 684-5057
DUMC 3707 Duke S Rm 1573,
Durham, NC
Specialties
Urology, Medical Oncology
Gender
Male
Languages
German, Spanish, Tagalog, Chinese
Education
Medical School: Jefferson Med Coll-Thos Jefferson Univ, Philadelphia Pa 19107
Graduation Year: 1982
Hospital
Hospital: Walter Reed Army Med Ctr, Washington, Dc

Data Provided by:
David Mois Albala, MD
(919) 684-5416
DUMC 3457 Rm 1112 Green Zone,
Durham, NC
Specialties
Urology
Gender
Male
Education
Medical School: Mi State Univ Coll Of Human Med, East Lansing Mi 48824
Graduation Year: 1983

Data Provided by:
Roger Lu Sur, MD
(919) 681-5506
DUMC 3167,
Durham, NC
Specialties
Urology
Gender
Male
Education
Medical School: Eastern Va Med Sch Of The Med Coll Of Hampton Roads, Norfolk Va 23501
Graduation Year: 1993

Data Provided by:
Glenn Preminger
(919) 620-4467
2100 Erwin Rd
Durham, NC
Specialty
Urology

Data Provided by:
Craig Francis Donatucci, MD
(919) 684-2127
Div Of Urol Box 3274,
Durham, NC
Specialties
Urology
Gender
Male
Education
Medical School: Temple Univ Sch Of Med, Philadelphia Pa 19140
Graduation Year: 1979

Data Provided by:
Michael Nicolo Ferrandino
(919) 684-8111
1000 Trent Dr
Durham, NC
Specialty
Urology

Data Provided by:
Data Provided by:

Chemo Regimen for Ovarian Cancer

Provided By:

SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say.

Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings.

This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous infusion) on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

The patients in the dose-dense group had longer median progression-free survival than those in the standard treatment group (28 months versus 17 months), and longer overall survival at three years (72 percent versus 65 percent). This means that women in the dose-dense group had a 29 percent lower risk of cancer progression and a 25 percent lower risk of death, the authors explained.

Toxicity forced 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment, the researchers noted. Severe anemia occurred in 214 patients (69 percent) in the dose-dense group and in 137 (44 percent) of the standard therapy group.

The survival benefits seen in the dose-dense group are rare in patients with advanced ovarian cancer, and this regimen offers a new treatment option for women with advanced epithelial ovarian cancer, concluded Dr. Noriyuki Katsumata, of the National Cancer Center Hospital in Tokyo, and colleagues.

The study, published in an upcoming print issue of The Lancet, was released online Sunday to coincide with the European Cancer Organization meeting held Sept. 20 to 24 in Berlin.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer," Dr. Michael A. Bookman, of the Arizona Cancer Center in Tucson, wrote in an accompanying commentary in The Lancet.

More information

The U.S. National Cancer Institute has more about ovarian cancer.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com